Resumen
Cold atmospheric plasma (CAP) is a promising tool to overcome certain cancerous and precancerous conditions in dermatology. A scheme of transferred CAP was first developed to treat melanoma (B16F10) skin cancer cells as well as non-malignant (L929) cells in vitro. CAP was transferred using a silicone tube with a jet system that was developed and was assessed as to whether it could generate reactive oxygen and nitrogen species (RONS) at near-room temperature. The transferred CAP was characterized electrically and spectroscopically. Biological data showed that the transferred CAP killed cancer cells but not non-malignant (L929) cells. Plasma treatment was effective with a time duration of 30 s, whereas non-malignant (L929) cells were less damaged during plasma treatment. In addition, catalase (CAT) enzyme was applied to neutralize and detoxify the RONS generated by the transferred CAP. These findings suggest that transferred CAP can be considered a melanoma cancer therapy.